Heritage’s Canadian launch of their EndoDNA test came in late 2019 through their partly owned subsidiary Endocanna Health. The test can be found on endodna.com, and is used to analyze over 500 genes and more than 550,000 Single Nucleotide Polymorphisms in the human body to provide a report indicating how each person’s individual DNA interacts with cannabinoids and terpenes.
“EndoDNA is truly a personalized experience when it comes to selecting cannabis products with the right cannabinoid profile and assists with choosing formulation, dosage, and best delivery method for consumers needs. Finding the right product for specific needs can be challenging and now with Purefarma and Pura Vida added to the products offered on myDNA.live, consumers will have access to a greater selection of high quality products,” said Len May, Endocanna Health co-founder and CEO.
Heritage is a cannabis company that deals primarily in production and sale of medical and recreational hemp and cannabis based products and services. They go a little beyond that, though, with services like their personalized DNA test in which they try to specifically tailor each individual’s experience to how their endocannabinoid system interacts with certain chemicals. Nobody else does that. They operate through their subsidiaries, Voyage Cannabis and CannaCure.
The test gives users personalized output based on results, and also includes genetically aligned product recommendations, which include their Purefarma and Pura Vida products, intended to give the best possible experience.
Heritage is up 10.3% on the news, now trading at $0.16.
Full disclosure: Heritage Cannabis Holdings is an equity.guru marketing client.